ReviewCurrent microbiology2026
The Crosstalk Role of Intestinal Barrier Damage in the Gut-Organ Axis and its Potential Therapeutic Implications.
Review in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal barrier damage is a pivotal mediator of gut-organ crosstalk and a key contributor to systemic disease. This review systematically summarizes the structural organization of the intestinal barrier, including the mucus layer, epithelial tight junctions, and the lamina propria immune network, and highlights their coordinated roles in regulating intestinal barrier dysfunction and immune homeostasis. Disruption of barrier integrity facilitates the translocation of microbial products, cytokines, and metabolites, thereby promoting systemic inflammation and the pathogenesis of multi-organ diseases, including liver injury, pancreatitis, and cardiovascular disorders. Emerging evidence underscores the critical roles of gut microbiota, immune signaling pathways, and metabolic factors in barrier regulation. Advances in single-cell and spatial omics, together with artificial intelligence (AI)-driven multi-omics integration, are providing novel insights into the cellular heterogeneity and molecular mechanisms underlying barrier dysfunction. Therapeutic strategies targeting barrier restoration-including microbiota-based interventions and pharmacological approaches-show promising potential but require further clinical validation. This review provides a comprehensive framework for understanding intestinal barrier biology and its translational relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.